India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

The collaboration combines Pieris drug discovery and early development capabilities with Cadilas expertise in biologics ... in cycle time of key products.In year 2022, Zydus Animal Health and ...

Under the company’s Biologics business, it produces, develops and markets biosimilar products for oncology ... Mankind Pharma Ltd, Zydus Lifesciences Ltd, Lupin Ltd. Who is/are the promoter ...

Zydus Biologics is a rapidly growing eatablishment, manufacturing 14 commercial products (mAbs, cytokines, ADCs, and other recombinant therapeutics).

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025, Zydus Lifesciences Ltd said in a regulatory filing. Template formulary is a ...

Elliott said Frontier Biologics produces two products: an allograft patch, which is made from amniotic material and can be used to treat open wounds such as diabetic ulcers, and a fluid product ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

The US FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.